
Chlorpromazine
Description
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, this compound's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. This compound has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
This compound is a Phenothiazine.
This compound is a phenothiazine that was once the most commonly prescribed antipsychotic agent, but that is now rarely used. This compound can cause mild and transient serum enzyme elevations and is also a well known cause of clinically apparent acute and chronic cholestatic liver injury.
This compound is a phenothiazine and traditional antipsychotic agent with anti-emetic activity. This compound exerts its antipsychotic effect by blocking postsynaptic dopamine receptors in cortical and limbic areas of the brain, thereby preventing the excess of dopamine in the brain. This leads to a reduction in psychotic symptoms, such as hallucinations and delusions. This compound appears to exert its anti-emetic activity by blocking the dopamine receptors in the chemical trigger zone (CTZ) in the brain, thereby relieving nausea and vomiting.
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class this compound's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. This compound has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
See also: Phenothiazine (subclass of); this compound Hydrochloride (has salt form) ... View More ...
Properties
IUPAC Name |
3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine | |
---|---|---|
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI |
InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3 | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
InChI Key |
ZPEIMTDSQAKGNT-UHFFFAOYSA-N | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Canonical SMILES |
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Molecular Formula |
C17H19ClN2S | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
DSSTOX Substance ID |
DTXSID0022808 | |
Record name | Chlorpromazine | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID0022808 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Molecular Weight |
318.9 g/mol | |
Source | PubChem | |
URL | https://pubchem.ncbi.nlm.nih.gov | |
Description | Data deposited in or computed by PubChem | |
Physical Description |
Solid | |
Record name | Chlorpromazine | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014620 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Boiling Point |
200-205 °C at 8.00E-01 mm Hg, BP: 200-205 °C at 0.8 mm Hg | |
Record name | Chlorpromazine | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00477 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Chlorpromazine | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3033 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Solubility |
Very soluble in ethanol, ether, benzene and chloroform; soluble in dilute hydrochloric acid, In water, 2.55X10-3 g/L (2.55 mg/L) at 24 °C, 4.17e-03 g/L | |
Record name | Chlorpromazine | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00477 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Chlorpromazine | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3033 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Record name | Chlorpromazine | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014620 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Color/Form |
Oily liquid, White, crystalline solid | |
CAS No. |
34468-21-8, 50-53-3 | |
Record name | 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-, radical ion(1+) | |
Source | CAS Common Chemistry | |
URL | https://commonchemistry.cas.org/detail?cas_rn=34468-21-8 | |
Description | CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society. | |
Explanation | The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. | |
Record name | Chlorpromazine | |
Source | CAS Common Chemistry | |
URL | https://commonchemistry.cas.org/detail?cas_rn=50-53-3 | |
Description | CAS Common Chemistry is an open community resource for accessing chemical information. Nearly 500,000 chemical substances from CAS REGISTRY cover areas of community interest, including common and frequently regulated chemicals, and those relevant to high school and undergraduate chemistry classes. This chemical information, curated by our expert scientists, is provided in alignment with our mission as a division of the American Chemical Society. | |
Explanation | The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. | |
Record name | Chlorpromazine [USP:INN:BAN] | |
Source | ChemIDplus | |
URL | https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000050533 | |
Description | ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system. | |
Record name | Chlorpromazine cation radical | |
Source | ChemIDplus | |
URL | https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0034468218 | |
Description | ChemIDplus is a free, web search system that provides access to the structure and nomenclature authority files used for the identification of chemical substances cited in National Library of Medicine (NLM) databases, including the TOXNET system. | |
Record name | Chlorpromazine | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00477 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | chlorpromazine | |
Source | DTP/NCI | |
URL | https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=756689 | |
Description | The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. | |
Explanation | Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. | |
Record name | chlorpromazine | |
Source | DTP/NCI | |
URL | https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=167745 | |
Description | The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. | |
Explanation | Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. | |
Record name | Chlorpromazine | |
Source | EPA DSSTox | |
URL | https://comptox.epa.gov/dashboard/DTXSID0022808 | |
Description | DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology. | |
Record name | Chlorpromazine | |
Source | European Chemicals Agency (ECHA) | |
URL | https://echa.europa.eu/substance-information/-/substanceinfo/100.000.042 | |
Description | The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness. | |
Explanation | Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page. | |
Record name | CHLORPROMAZINE | |
Source | FDA Global Substance Registration System (GSRS) | |
URL | https://gsrs.ncats.nih.gov/ginas/app/beta/substances/U42B7VYA4P | |
Description | The FDA Global Substance Registration System (GSRS) enables the efficient and accurate exchange of information on what substances are in regulated products. Instead of relying on names, which vary across regulatory domains, countries, and regions, the GSRS knowledge base makes it possible for substances to be defined by standardized, scientific descriptions. | |
Explanation | Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. | |
Record name | Chlorpromazine | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3033 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Record name | Chlorpromazine | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014620 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Melting Point |
177-178, About 60 °C, < 25 °C | |
Record name | Chlorpromazine | |
Source | DrugBank | |
URL | https://www.drugbank.ca/drugs/DB00477 | |
Description | The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. | |
Explanation | Creative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode) | |
Record name | Chlorpromazine | |
Source | Hazardous Substances Data Bank (HSDB) | |
URL | https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3033 | |
Description | The Hazardous Substances Data Bank (HSDB) is a toxicology database that focuses on the toxicology of potentially hazardous chemicals. It provides information on human exposure, industrial hygiene, emergency handling procedures, environmental fate, regulatory requirements, nanomaterials, and related areas. The information in HSDB has been assessed by a Scientific Review Panel. | |
Record name | Chlorpromazine | |
Source | Human Metabolome Database (HMDB) | |
URL | http://www.hmdb.ca/metabolites/HMDB0014620 | |
Description | The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body. | |
Explanation | HMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications. | |
Historical Context and Paradigm Shift in Neuropsychopharmacology with Chlorpromazine
Pre-Chlorpromazine Psychiatric Treatment Modalities
Prior to the 1950s, the treatment of mental illness was vastly different from contemporary practices. Individuals experiencing severe psychiatric symptoms were often cared for by their families, but in more challenging cases, they might be relegated to almshouses or even jails nih.gov. The prevailing understanding of mental illness often linked it to moral or spiritual failings, leading to treatments that could involve punishment and shame nih.gov.
The 19th century saw the rise of the "Moral Treatment" movement, which advocated for more humane care within specialized institutions known as asylums upenn.edunih.gov. This approach emphasized kindness, structured environments, meaningful work, and gentler forms of restraint, aiming to foster recovery through rational appeal upenn.edu. Early institutions like the Friends Asylum, established in 1814, and later state-supported asylums, were built with the intention of providing such care upenn.edunih.gov. However, as the number of patients grew, many asylums became severely overcrowded and underfunded. This led to a decline in the quality of care, with issues of poor sanitation, lack of hygiene, and patient mistreatment becoming prevalent wikipedia.orgcsp.edu. In many instances, the focus shifted from active treatment to custodial care, with asylums housing individuals deemed "senile" or "incurable" nih.gov.
The therapeutic interventions available were largely non-pharmacological or physical in nature. These included isolation, restraint, and various physical methods such as ice water baths, bloodletting, purging, and even more invasive procedures like lobotomies and insulin coma therapy csp.edu. While some early attempts at pharmacological intervention involved sedatives and hypnotics like chloral hydrate and barbiturates, their utility was primarily for sedation rather than therapeutic effect scielo.br. By the mid-20th century, despite the proliferation of asylums, many patients remained without effective treatment for their severe mental conditions wikipedia.org.
Genesis and Early Pharmacological Investigations of Chlorpromazine
The development of this compound stemmed from research into phenothiazine derivatives, initially explored for their antihistamine and antiemetic properties.
Derivation from Phenothiazine Chemistry and Antihistamine Research
This compound (CPZ) is a synthetic compound derived from the phenothiazine chemical structure physio-pedia.comwikipedia.org. Phenothiazines were initially investigated for their potential as antihistamines, with compounds like promethazine showing promise in this area scielo.br. Researchers at the French pharmaceutical company Rhône-Poulenc were actively exploring derivatives of phenothiazine for various medical applications scielo.br. This line of research led to the synthesis of this compound, which was found to possess potent antihistaminic and sedative effects scielo.br.
Initial Observations in Anesthesiology and "Artificial Hibernation"
The therapeutic potential of this compound beyond its antihistaminic properties began to emerge through observations in surgical settings. French surgeon Henri Laborit, in his work with surgical shock and anesthesia in the late 1940s and early 1950s, explored the use of promethazine and later this compound as part of a "lytic cocktail" scielo.br. Laborit hypothesized that this combination could induce a state of "artificial hibernation," a controlled hypothermia that would reduce metabolic activity and protect the body during surgery scielo.br.
Patients treated with this compound in this context exhibited a remarkable calmness and detachment, a state Laborit termed "desintéressement" scielo.br. This profound calming effect, even in the absence of deep anesthesia, suggested that this compound might have significant psychotropic properties. These observations in anesthesiology laid the groundwork for exploring its use in psychiatric disorders, particularly those characterized by agitation and severe behavioral disturbances scielo.br.
Introduction of this compound into Psychiatric Practice
The serendipitous observations from anesthesiology quickly propelled this compound into psychiatric research and clinical trials, leading to a revolution in mental healthcare.
Pioneering Clinical Applications in Psychotic Disorders
Following Laborit's findings, French psychiatrists Jean Delay and Pierre Deniker, along with their colleagues, began systematically investigating this compound's effects on patients with severe mental illnesses, particularly those suffering from psychosis and schizophrenia scielo.br. Their early clinical trials, starting in 1952, demonstrated that this compound could significantly reduce psychotic symptoms such as hallucinations, delusions, agitation, and disorganized behavior scielo.br. Patients who had been severely incapacitated by their conditions often showed marked improvement, becoming more communicative, organized, and responsive to their environment scielo.br.
This compound's ability to calm agitated patients and reduce the severity of psychotic symptoms was unprecedented. It offered the first effective pharmacological tool to manage the core symptoms of schizophrenia and other psychotic disorders, moving away from purely custodial or physically intrusive treatments scielo.brphysio-pedia.comwikipedia.org. This marked a pivotal shift from containment to treatment, offering hope for recovery and improved quality of life for many individuals previously considered untreatable wikipedia.org.
International Dissemination and Acceptance in Psychiatry
The groundbreaking results from French clinical trials rapidly led to the international dissemination of this compound. It was introduced into clinical practice in the United States in 1954 under the brand name Thorazine wikipedia.org. The drug's efficacy in managing severe psychiatric symptoms, particularly psychosis, led to its widespread adoption by psychiatrists worldwide nih.govupenn.edunih.govwikipedia.org.
This compound's introduction is widely credited with initiating the psychopharmacological revolution, fundamentally changing how mental illnesses were understood and treated scielo.br. It facilitated the deinstitutionalization movement by making it possible for many patients to live outside of psychiatric hospitals, and it spurred extensive research into other psychoactive medications wikipedia.org. By the late 1950s and early 1960s, this compound had become a cornerstone of psychiatric treatment, a benchmark against which new antipsychotic medications would be measured cochranelibrary.com. Its impact was so profound that it is often referred to as the first "major tranquilizer" and a drug that redefined the possibilities of psychiatric care scielo.br.
Neuropharmacological Mechanisms of Action of Chlorpromazine
Dopaminergic Receptor Antagonism as a Primary Mechanism
The antipsychotic properties of chlorpromazine are predominantly attributed to its ability to block dopamine receptors. numberanalytics.comuzh.ch This antagonism reduces dopaminergic neurotransmission, a key element in the dopamine hypothesis of schizophrenia, which posits that excessive dopamine activity in certain brain regions contributes to psychotic symptoms. numberanalytics.compatsnap.com All commercially available antipsychotic medications reduce dopaminergic neurotransmission to some extent. aspet.org
This compound demonstrates a broad-spectrum antagonism across dopamine receptor subtypes. nih.gov It acts as a blocking agent on D1, D2, D3, and D4 receptors. wikipedia.orgdrugbank.commdpi.com It is a particularly effective antagonist of D2 dopamine receptors and similar receptors like D3 and D5. wikipedia.org Unlike many other typical antipsychotics, this compound also possesses a high affinity for D1 receptors. wikipedia.org The dopamine receptor family is divided into D1-like (D1 and D5) and D2-like (D2, D3, D4) receptors, which differ in their signaling pathways. nih.govmdpi.com this compound's interaction with this wide array of dopamine receptors underlies its antipsychotic effects. nih.gov Studies have reported a binding affinity (Ki) of 3–23 nM for D2 dopamine receptors. oncotarget.com
Receptor Subtype | Interaction | Reported Affinity (Ki) |
---|---|---|
D1 | Antagonist | High Affinity wikipedia.org |
D2 | Antagonist | ~75 nM medchemexpress.com, High Affinity wikipedia.orgoncotarget.comkcl.ac.uk |
D3 | Antagonist | Effective Antagonist wikipedia.org |
D4 | Antagonist | Antagonist wikipedia.orgdrugbank.com |
D5 | Antagonist | Effective Antagonist wikipedia.org |
This compound is classified as a low-potency typical antipsychotic. wikipedia.orgwikipedia.org A significant correlation exists between the clinical potency of typical antipsychotics and their affinity for the D2 receptor. wikipedia.org High-potency antipsychotics like haloperidol generally show higher binding affinity for D2 receptors compared to low-potency agents like this compound. kcl.ac.ukwikipedia.org
Second-generation, or "atypical," antipsychotics were developed to have a different receptor binding profile, notably a lower affinity for the D2 receptor and a relatively greater affinity for other neuroreceptors, particularly serotonin receptors. nih.gov For instance, newer antipsychotics like risperidone, olanzapine, and clozapine display a low binding affinity for D2 receptors. kcl.ac.uk A key pharmacological property highlighted for atypical activity is a low ratio of D2 to 5-HT2A receptor antagonism, a characteristic of these newer agents. nih.gov Interestingly, this compound tends to exert a greater effect at serotonin receptors than at D2 receptors, which is the opposite of other typical antipsychotics. wikipedia.org This makes its receptor profile somewhat similar to that of atypical antipsychotics. wikipedia.org
Compound | Class | D2 Receptor Affinity | Serotonin 5-HT2A Receptor Affinity | D2/5-HT2A Ratio |
---|---|---|---|---|
This compound | Typical (Low-Potency) | Moderate cambridge.org | Potent Antagonist cambridge.org | Low wikipedia.org |
Haloperidol | Typical (High-Potency) | High kcl.ac.uk | Weaker than D2 Affinity nih.gov | High |
Clozapine | Atypical | Low kcl.ac.uk | High | Low nih.gov |
Olanzapine | Atypical | Low (but higher than Clozapine) kcl.ac.ukpsychiatryonline.org | High psychiatryonline.org | Low nih.gov |
Risperidone | Atypical | Low kcl.ac.uk | High | Low nih.gov |
The brain contains several distinct dopaminergic pathways, and the effects of this compound are pathway-dependent. psychdb.com
Mesolimbic Pathway: This pathway projects from the Ventral Tegmental Area (VTA) to the nucleus accumbens and is associated with emotion and reward. psychdb.com Excessive dopamine activity in the mesolimbic system is linked to the positive symptoms of psychosis (e.g., hallucinations and delusions). patsnap.comaspet.orgpsychdb.com this compound's primary antipsychotic effect is attributed to its blockade of D2 receptors in the mesolimbic pathway, which reduces this hyperactivity. patsnap.comwikipedia.orginchem.orgfrontiersin.orgijraset.com
Nigrostriatal Pathway: This pathway is part of the extrapyramidal nervous system and is crucial for motor control. The blockade of D2 receptors by this compound in the nigrostriatal system is not related to its antipsychotic effects but is instead responsible for producing extrapyramidal side effects. patsnap.comaspet.orgwikipedia.orginchem.org
Differential Affinity and Receptor Selectivity Profiles Compared to Other Antipsychotics
Serotonergic Receptor Interactions
This compound acts as an antagonist at several serotonin receptor subtypes, including 5-HT2, 5-HT6, and 5-HT7 receptors. nih.govwikipedia.orgmdpi.com Its antagonism at 5-HT2A receptors is particularly noteworthy and is a feature it shares with many atypical antipsychotics. medchemexpress.comcambridge.orgnih.govmedchemexpress.com This action at serotonin receptors contributes to anxiolytic and antiaggressive properties. wikipedia.orgdrugbank.com While most typical and atypical antipsychotics are antagonists at 5-HT7 receptors, this compound is included in this group. frontiersin.org
The antagonism of serotonin receptors, particularly the 5-HT2A subtype, is believed to contribute to this compound's antipsychotic efficacy. patsnap.com This mechanism is thought to be especially relevant for improving negative and cognitive symptoms of schizophrenia, which are often less responsive to pure D2 antagonism. patsnap.com The blockade of 5-HT2A receptors is a defining characteristic of atypical antipsychotics, which are noted for a lower incidence of extrapyramidal symptoms. nih.govnih.gov
The serotonergic system modulates the activity of several other neurotransmitter systems, including dopamine. frontiersin.org By acting on serotonin receptors, this compound can indirectly influence dopaminergic pathways. For example, 5-HT2A receptor antagonism is thought to enhance dopamine release in certain brain regions, which may help to alleviate some of the effects of D2 blockade. nih.gov This complex interplay between the serotonin and dopamine systems is central to the mechanism of action of many antipsychotic drugs. tandfonline.com Antagonism at 5-HT6 and 5-HT7 receptors may also contribute to beneficial effects on cognition. nih.gov
Antagonism at 5-HT2, 5-HT6, and 5-HT7 Serotonin Receptors
Adrenergic Receptor Antagonism (Alpha-Adrenergic)
This compound demonstrates potent antagonism at alpha-adrenergic receptors, particularly the α1-adrenergic subtype. inchem.orgmdpi.com This blockade disrupts the normal signaling of norepinephrine and epinephrine, key neurotransmitters in the sympathetic nervous system. The antagonism of α1-adrenergic receptors by this compound leads to vasodilation, a relaxation of the smooth muscle in blood vessels, which can result in a drop in blood pressure (orthostatic hypotension). patsnap.com
Studies have shown that this compound has a high affinity for α1a-adrenergic receptors. caymanchem.com The kinetics of this receptor blockade reveal that the onset of action against phenylephrine, an alpha-adrenergic agonist, is slower compared to its effects on other receptors. nih.gov Similarly, the offset of the blockade is also significantly slower for alpha-adrenergic receptors, suggesting a less readily reversible interaction. nih.gov This sustained antagonism contributes to some of the cardiovascular side effects associated with this compound. Furthermore, research comparing central and peripheral alpha-adrenergic receptor antagonism has indicated that central blockade can influence regional cerebral blood flow. nih.gov
Histaminergic H1 Receptor Blockade
A prominent feature of this compound's pharmacological profile is its potent antagonism of histamine H1 receptors. mdpi.compatsnap.com This action is responsible for the sedative and calming effects often observed with its use. patsnap.comnumberanalytics.com The blockade of H1 receptors in the central nervous system is a key contributor to the drug's tranquilizing properties. physio-pedia.com
The affinity of this compound for the H1 receptor is significant. caymanchem.com Research has demonstrated a correlation between the affinity for H1 receptors and the magnitude of histamine efflux in the medial prefrontal cortex for several antipsychotic drugs, including this compound. frontiersin.org The kinetics of H1 receptor blockade by this compound show a relatively rapid onset and offset compared to its effects on alpha-adrenergic receptors. nih.gov This antihistaminic activity also contributes to its antiemetic (anti-nausea and vomiting) effects, which result from the combined blockade of H1, dopamine D2, and muscarinic M1 receptors in the vomiting center. nih.gov
Muscarinic Cholinergic Receptor Antagonism (M1)
This compound also functions as an antagonist at muscarinic cholinergic receptors, including the M1 subtype. mdpi.comnih.gov This anticholinergic activity contributes to both its therapeutic profile and its side effects. The blockade of M1 receptors can help to mitigate some of the extrapyramidal side effects associated with dopamine D2 receptor antagonism. patsnap.com
However, this muscarinic blockade is also responsible for a range of peripheral and central side effects, such as dry mouth, blurred vision, constipation, and urinary retention. mdpi.compatsnap.com Studies have determined the pA2 value, a measure of antagonist potency, for this compound at muscarinic receptors to be 7.17. nih.gov The kinetics of muscarinic receptor blockade are characterized by a relatively fast onset and offset. nih.gov It is important to note that while this compound is an antagonist, other compounds can act as agonists at these receptors, producing opposing effects.
Modulation of Glutamatergic System Activity
Emerging research has highlighted the significant interaction of this compound with the glutamatergic system, the primary excitatory neurotransmitter system in the brain. clinmedjournals.orgijpp.com This modulation adds another layer of complexity to its mechanism of action beyond the traditional understanding centered on dopamine and serotonin antagonism. clinmedjournals.org
Effects on NMDA Receptor Mechanisms, Including Zn Site Interactions
This compound also significantly impacts N-methyl-D-aspartate (NMDA) receptor function. clinmedjournals.orgnih.gov It can act as an antagonist at NMDA receptors, in part by interacting with the zinc (Zn) binding site on the receptor complex. nih.govresearchgate.netresearchgate.net This interaction is complex, with this compound exhibiting both Zn++-like and Mg++-like effects at different concentrations. nih.gov At low concentrations, it slows the dissociation of [3H]MK801, a marker for the NMDA receptor channel, while at higher concentrations, it increases the dissociation rate. nih.gov This suggests a multifaceted interaction with the NMDA receptor complex. The inhibition of NMDA receptors by this compound occurs at clinically relevant low micromolar concentrations and displays a voltage- and magnesium-dependent open channel blocking mechanism. researchgate.netnih.gov
Implications for Excitatory Neurotransmission and Neurotrophic Effects
The modulation of both AMPA and NMDA receptors by this compound has significant implications for excitatory neurotransmission and neurotrophic processes. ijpp.comclinmedjournals.org By altering the activity of these critical glutamate receptors, this compound can influence synaptic plasticity, which is fundamental for learning and memory. clinmedjournals.org Some studies have described the effects of this compound on glutamatergic receptor mechanisms as having "neurotrophic effects," as it modifies the amplitude and temporal characteristics of receptor activity. clinmedjournals.orgijpp.comclinmedjournals.org
GABAergic System Modulation
This compound (CPZ), a widely used antipsychotic medication, is known to interact with various ligand- and voltage-gated channels. nih.gov Its influence extends to the GABAergic system, the primary inhibitory neurotransmitter system in the central nervous system. Research indicates that this compound modulates the function of GABA-A receptors, the main ionotropic receptors for gamma-aminobutyric acid (GABA), thereby affecting inhibitory neurotransmission. nih.govjneurosci.orgfrontiersin.org
Influence on GABA-A Receptor Binding and Unbinding Kinetics
Studies utilizing patch-clamp techniques on cultured hippocampal neurons have revealed that this compound affects the binding and unbinding kinetics of GABA to GABA-A receptors. nih.govjneurosci.org Experimental data and model simulations suggest that this compound decreases the binding rate constant (k_on) and increases the unbinding rate constant (k_off) of GABA-A receptors. nih.govnih.govjneurosci.org
This alteration in kinetics has significant functional consequences. The reduction in the binding rate (k_on) by this compound makes the binding reaction a rate-limiting step. nih.govjneurosci.org Consequently, the brief presence of GABA in the synaptic cleft during a miniature inhibitory postsynaptic current (mIPSC) is insufficient to activate the receptors to the same degree as in control conditions. nih.govnih.govjneurosci.org This leads to a reduction in the amplitude of mIPSCs. nih.gov
Simultaneously, the increase in the unbinding rate (k_off) is the proposed mechanism for the accelerated decay phase of mIPSCs observed in the presence of this compound. nih.govnih.govjneurosci.org This faster unbinding of GABA from the receptor shortens the duration of the channel opening, leading to a quicker decay of the inhibitory current. nih.gov The effect of this compound on the rise time of GABA-evoked currents is dose-dependent, with higher concentrations causing a more significant slowing of the current onset. nih.govjneurosci.org
Table 1: Effect of this compound on the Rise Time of GABA-Evoked Currents
This compound Concentration (μM) | 10-90% Rise Time (msec) |
---|---|
0 (Control) | 1.12 ± 0.08 |
100 | 1.82 ± 0.06 |
Data from experiments on cultured hippocampal neurons. The rise time of GABA-evoked currents was measured in the absence and presence of 100 μM this compound. The increase in rise time indicates a slower onset of the current. nih.gov
Effects on Miniature Inhibitory Postsynaptic Currents (mIPSCs)
This compound has been shown to significantly alter the characteristics of miniature inhibitory postsynaptic currents (mIPSCs) in cultured hippocampal neurons. nih.govjneurosci.org These currents represent the postsynaptic response to the spontaneous release of a single quantum of GABA from a presynaptic terminal.
Specifically, this compound reduces the amplitude and accelerates the decay of mIPSCs in a dose-dependent manner. nih.govjneurosci.org For instance, bath application of this compound at concentrations of 10, 30, and 100 μM resulted in a progressive decrease in mIPSC amplitude. jneurosci.org While 100 μM this compound reduced the mIPSC amplitude by approximately 90%, it only caused about a 30% depression of responses evoked by direct application of GABA, highlighting a more pronounced effect on synaptic currents. nih.govjneurosci.org
The acceleration of the mIPSC decay kinetics is also a prominent effect of this compound. nih.govjneurosci.org This is evident when comparing the normalized current traces in control conditions and in the presence of the drug, where the decay phase is clearly faster with this compound. nih.gov This effect, as mentioned earlier, is attributed to the increased unbinding rate of GABA from its receptors. nih.govjneurosci.org
Table 2: Dose-Dependent Effect of this compound on mIPSC Amplitude
This compound Concentration (μM) | mIPSC Amplitude (as a fraction of control) |
---|---|
10 | 0.74 ± 0.1 |
30 | 0.69 ± 0.12 |
100 | 0.09 ± 0.07 |
Data showing the dose-dependent reduction in the amplitude of miniature inhibitory postsynaptic currents (mIPSCs) in the presence of varying concentrations of this compound. jneurosci.org
Cellular and Subcellular Mechanisms of Chlorpromazine Action
Biophysical Interactions with Cellular Membranes
The initial point of contact for chlorpromazine with a cell is its membrane. The drug's amphiphilic nature, possessing both hydrophobic and hydrophilic regions, facilitates its interaction with and penetration into the lipid bilayer, leading to significant alterations in membrane properties. portlandpress.comtandfonline.comphysiology.org
Alterations in Membrane Permeability and Fluidity
This compound has been demonstrated to increase the permeability and fluidity of cellular membranes. nih.govnih.gov This effect is concentration-dependent. tandfonline.comnih.gov Studies using rat brain slices have shown that CPZ can induce the leakage of intracellular components, suggesting the formation of transient pores or a general destabilization of the membrane. nih.gov This increased permeability is thought to be a result of the drug intercalating into the lipid bilayer, which disrupts the ordered packing of phospholipids. oncotarget.comresearchgate.net
The interaction of this compound with the membrane also leads to an increase in membrane fluidity. nih.gov This has been observed through techniques such as fluorescence polarization. nih.govnih.gov An increase in fluidity implies a more disordered state of the lipid acyl chains within the membrane. nih.govoncotarget.com This fluidizing effect is influenced by the lipid composition of the membrane, particularly the cholesterol content. annualreviews.org For instance, in membranes with low cholesterol, this compound can cause an ordering effect at lower concentrations, which transitions to a disordering effect at higher concentrations or in high-cholesterol membranes. annualreviews.org
Property | Effect | Method of Observation | Key Findings | References |
---|---|---|---|---|
Permeability | Increased | Leakage assays (e.g., calcein, [(18)F]FDG-6-phosphate) | CPZ induces leakage of intracellular molecules, suggesting membrane destabilization and pore formation. | nih.govoncotarget.com |
Fluidity | Increased | Fluorescence polarization/anisotropy | CPZ decreases the order of lipid acyl chains, leading to a more fluid membrane state. | nih.govnih.gov |
Interactions with Negatively Charged Membrane Phospholipids and Polarity Shifts
This compound, being a cationic amphiphile at physiological pH, exhibits a strong affinity for negatively charged phospholipids, such as phosphatidylserine, which are often enriched in the inner leaflet of the plasma membrane. portlandpress.comnih.govnih.gov This electrostatic attraction plays a crucial role in its membrane interactions. nih.govresearchgate.net
The binding of this compound to these anionic lipids can neutralize their negative charge. oncotarget.com This neutralization has significant consequences for membrane-associated proteins that rely on electrostatic interactions for their localization and function. oncotarget.com A notable example is the oncogenic protein K-Ras4B(G12V), which anchors to the membrane through interactions with negatively charged phospholipids. oncotarget.com this compound has been shown to dislodge K-Ras4B(G12V) from the membrane by neutralizing these charges, thereby inhibiting its signaling functions. oncotarget.com
This interaction also leads to a shift in the polarity of the membrane environment. rsc.org The insertion of the hydrophobic tricyclic ring of this compound into the lipid bilayer, coupled with the presence of its polar side chain at the interface, alters the local dielectric properties. tandfonline.comresearchgate.net This change in polarity can be observed by the enhanced fluorescence of this compound itself upon membrane insertion. rsc.org The drug's presence at the lipid interfacial region allows it to interact with both the headgroups and the acyl tails of the phospholipids, further contributing to the destabilization and altered polarity of the membrane. rsc.org
Modulation of Intracellular Signaling Pathways
Beyond its direct effects on the cell membrane, this compound penetrates the cell and modulates several critical intracellular signaling pathways. These pathways are integral to cellular processes such as growth, proliferation, and metabolism.
Effects on Calcium Ion (Ca²⁺) Signaling Pathways
This compound has complex and multifaceted effects on intracellular calcium (Ca²⁺) signaling. It has been shown to inhibit store-operated calcium entry (SOCE), a crucial mechanism for replenishing intracellular calcium stores and sustaining calcium signals. nih.gov In PC12 cells, this compound inhibited the sustained phase of Ca²⁺ increase induced by bradykinin, without affecting the initial release from internal stores. nih.gov This suggests a direct inhibitory effect on the channels responsible for SOCE. nih.gov
Conversely, in human glioblastoma cells (GBM 8401), this compound has been found to increase intracellular Ca²⁺ concentrations. nih.govresearchgate.net This increase is mediated by both Ca²⁺ influx through store-operated Ca²⁺ channels and phospholipase C (PLC)-dependent Ca²⁺ release from the endoplasmic reticulum. nih.govresearchgate.net The chelation of this excess intracellular Ca²⁺ was shown to reduce this compound-induced cytotoxicity in these cancer cells, indicating that the dysregulation of Ca²⁺ homeostasis is a key component of its anti-tumor activity. nih.gov
Cell Type | Effect on Intracellular Ca²⁺ | Proposed Mechanism | References |
---|---|---|---|
PC12 Cells | Inhibition of sustained Ca²⁺ increase | Inhibition of store-operated calcium entry (SOCE) | nih.gov |
GBM 8401 Human Glioblastoma Cells | Increase in intracellular Ca²⁺ | Ca²⁺ influx via SOCE and PLC-dependent release from the endoplasmic reticulum | nih.govresearchgate.net |
Mechanistic Target of Rapamycin Complex 1 (mTORC1) Signaling Regulation
The mTORC1 signaling pathway is a central regulator of cell growth, proliferation, and metabolism. This compound has been identified as an inhibitor of the mTORC1 pathway in various cancer cell lines, including glioma and oral cancer cells. oncotarget.comresearchgate.netnih.gov It achieves this inhibition by reducing the phosphorylation levels of key downstream effectors of mTORC1, such as Akt and p70S6K. oncotarget.comnih.gov In PTEN-null glioma cells, where the Akt/mTOR pathway is constitutively active, this compound treatment led to cell cycle arrest and autophagic cell death. oncotarget.comoup.com The inhibition of mTORC1 signaling is a significant contributor to the anti-proliferative and pro-autophagic effects of this compound. nih.govoup.com
Induction of Transcription Factor EB (TFEB) Nuclear Translocation
Recent studies have revealed that this compound can induce the nuclear translocation of Transcription Factor EB (TFEB). frontiersin.orgnih.govrcsi.com TFEB is a master regulator of lysosome biogenesis and autophagy. frontiersin.org Under normal conditions, mTORC1 phosphorylates TFEB, retaining it in the cytoplasm. nih.gov By inhibiting mTORC1 activity, this compound prevents this phosphorylation, leading to TFEB's translocation into the nucleus. frontiersin.orgnih.gov This effect appears to be mediated through the Rag GTPases, which are upstream regulators of mTORC1. frontiersin.orgnih.gov Once in the nucleus, TFEB can activate the transcription of genes involved in autophagy and lysosomal function. nih.gov However, it has also been noted that while promoting the machinery for autophagy, this compound can also block the fusion of autophagosomes with lysosomes, leading to an accumulation of immature autophagosomes. frontiersin.org
Autophagy Pathway Modulation
This compound (CPZ) has been identified as a modulator of autophagy, a fundamental cellular process for the degradation and recycling of cellular components. Its effects are complex, influencing multiple stages of the autophagic pathway.
Blockade of Autophagosome-Lysosome Fusion
A primary mechanism underlying the accumulation of autophagosomes is the blockade of their fusion with lysosomes. researchgate.netnih.govmdpi.comoup.com This fusion is a critical step in the autophagic process, as the acidic environment and hydrolytic enzymes within the lysosome are necessary for the breakdown of the autophagosome's contents. By inhibiting this fusion, this compound effectively halts the final stage of autophagy, leading to a build-up of undegraded autophagic vesicles. researchgate.net This effect is similar to that of other agents known to disrupt lysosomal function, such as chloroquine. oup.combrieflands.com The inability of autophagosomes to merge with lysosomes results in a dysfunctional pathway where cellular waste is sequestered but not eliminated.
Role of Rag GTPases in Autophagic Impairment
Recent research has elucidated the role of Rag GTPases in the autophagic impairment caused by this compound. researchgate.netmdpi.comoup.com Rag GTPases are key regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway, which is a central controller of cell growth and autophagy. researchgate.net this compound treatment has been shown to induce the nuclear translocation of Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, in a manner dependent on Rag GTPases. researchgate.netmdpi.comoup.com Specifically, CPZ appears to decrease the activity of Rag GTPases, leading to the dissociation of mTORC1 from the lysosome and subsequent nuclear entry of TFEB. researchgate.net While this would typically promote autophagy, the concurrent blockade of autophagosome-lysosome fusion creates a state of autophagic stress. Interestingly, the expression of an active form of Rag GTPase heterodimers has been found to alleviate the accumulation of autophagosomes induced by CPZ, underscoring the significant contribution of the Rag GTPase-mTORC1-TFEB signaling axis to this compound-induced autophagic dysfunction. researchgate.netmdpi.com
Mitochondrial Function and Cellular Metabolism
This compound also exerts significant effects on mitochondrial function and cellular metabolism, targeting key components of the respiratory chain and influencing energy production pathways.
Inhibition of Cytochrome c Oxidase (CcO) Activity
This compound has been demonstrated to inhibit the activity of cytochrome c oxidase (CcO), also known as complex IV of the mitochondrial electron transport chain. nih.govnih.govoncotarget.com This inhibitory effect has been observed to be particularly selective in certain pathological contexts. For instance, in chemoresistant glioma cells, this compound selectively inhibits CcO activity, an effect not seen in their chemosensitive counterparts. nih.govnih.gov This selectivity is linked to the expression of different isoforms of a CcO subunit. Chemoresistant glioma cells often exhibit a switch from expressing the COX4-2 subunit isoform to the COX4-1 isoform. nih.govnih.gov Computer-simulated docking studies suggest that this compound binds more effectively to CcO containing the COX4-1 subunit. nih.govnih.gov The direct interaction and inhibition of CcO by this compound have been confirmed in studies using purified enzyme, with a reported IC50 value of 25.82 ± 3.75 μM for bovine heart CcO. nih.gov
Cell/Tissue Type | Condition | Effect on CcO Activity | Associated Findings |
Chemoresistant Glioma Cells | In vitro | Inhibition | Selective for cells expressing COX4-1 subunit |
Chemosensitive Glioma Cells | In vitro | No significant effect | Express COX4-2 subunit |
Bovine Heart | Purified enzyme | Inhibition (IC50: 25.82 ± 3.75 μM) | Direct interaction with CcO |
Rat Brain Mitochondria | In vitro | 50% inhibition at 50 μM | Early evidence of CcO inhibition |
Effects on Oxygen Consumption and Glucose Oxidation
This compound also influences glucose metabolism. Research indicates that it inhibits the oxidation of glucose. researchgate.netcapes.gov.br In guinea pig brain tissue, this compound was found to inhibit the oxidation of glucose via the tricarboxylic acid (TCA) cycle. capes.gov.br Furthermore, in canine thyroid slices, this compound blocked the TSH-induced stimulation of glucose-1-14C oxidation to 14CO2, suggesting an interference with metabolic pathways linked to specific cellular functions. oup.com While prolonged treatment with low doses of CPZ did not appear to alter glucose tolerance in human subjects, higher acute doses have been suggested to potentially inhibit insulin secretion and induce hyperglycemia. nih.gov
Parameter | System | Concentration | Effect |
Oxygen Consumption | Cultured Mammalian Cells | Not specified | Inhibition |
Isolated Rat Hepatocytes | >150 μM | Decrease | |
Isolated Rat Hepatocytes | 5 μM | Increase (succinate-stimulated) | |
Isolated Rat Liver Mitochondria | 20-100 μM (basal) | Increase | |
Isolated Rat Liver Mitochondria | 50-400 μM (uncoupled) | Inhibition | |
Leishmania donovani Promastigotes | 50 µg/ml | 87% reduction | |
Glucose Oxidation | Guinea Pig Brain Tissue | Not specified | Inhibition (via TCA cycle) |
Canine Thyroid Slices | 2x10⁻⁴M | Blockade of TSH-stimulated oxidation | |
Human Subjects (acute, high dose) | 50 mg infusion | Potential for hyperglycemia and inhibited insulin secretion |
Impact on Nucleic Acid Synthesis and Cell Proliferation
This compound (CPZ) demonstrates a significant capacity to interfere with fundamental cellular processes such as nucleic acid synthesis and cell proliferation. nih.gov These actions are central to its observed antitumor effects and have been documented across a variety of cell types and experimental systems. nih.govmdpi.com The compound's interference with DNA replication and the cell division cycle underscores its potential as a modulator of cell growth. nih.govresearchgate.net
Inhibition of DNA Synthesis and [³H]Thymidine Incorporation
One of the earliest recognized anticancer mechanisms of this compound is its ability to inhibit DNA synthesis. nih.gov This effect has been consistently observed in both cellular and cell-free systems, suggesting a direct interference with the enzymatic machinery of DNA replication. nih.govnih.gov
A common method to measure DNA synthesis is the [³H]thymidine incorporation assay, which tracks the integration of a radiolabeled nucleoside into newly synthesized DNA during cell division. thermofisher.comresearchgate.net Studies using this technique have provided quantitative evidence of this compound's inhibitory effects. For instance, early research in 1965 demonstrated that this compound reduces the incorporation of [³H]thymidine into human bone marrow cells. nih.govresearchgate.net
Further research has elaborated on this inhibitory action in various models:
In developing rat brains, this compound administration led to a severe and dose-dependent reduction in the rate of [³H]thymidine incorporation into DNA. nih.gov The synthesis rate dropped to less than 40% of control levels in the forebrain and 60% in the cerebellum within hours of administration. nih.gov
In the protozoan Tetrahymena, a 20-minute preincubation with 14.7 µM of this compound inhibited DNA synthesis by 46%. nih.gov The compound was also found to inhibit the incorporation of labeled thymidine into the thymidine triphosphate pool in this organism. nih.gov
In Meth A sarcoma cells, this compound was shown to inhibit DNA synthesis both in cell cultures and in isolated nuclei. nih.gov
Studies on the fungus Candida albicans also revealed that this compound affects DNA synthesis, which is linked to its antifungal activity. oup.comoup.com
This body of evidence confirms that this compound's impact on cell proliferation is directly linked to its capacity to halt or slow down the synthesis of DNA. nih.govtandfonline.com
Table 1: Effect of this compound on DNA Synthesis and [³H]Thymidine Incorporation in Various Cell Types
Cell Type/Organism | This compound Concentration/Dose | Observed Effect | Reference |
---|---|---|---|
Developing Rat Brain (in vivo) | 50 mg/kg | Severe reduction in [³H]thymidine incorporation; less than 40% of control in forebrain and 60% in cerebellum. | nih.gov |
Tetrahymena | 14.7 µM | 46% inhibition of DNA synthesis after 20-minute preincubation. | nih.gov |
Human Bone Marrow Cells | Not specified | Decreased [³H]thymidine incorporation. | nih.govresearchgate.net |
Meth A Sarcoma Cells | Not specified | Inhibited DNA synthesis in both cultured cells and isolated nuclei. | nih.gov |
Candida albicans | IC50 | Affects DNA synthesis (S phase). | oup.comoup.com |
Effects on Cell Cycle Parameters and Mitotic Activity
This compound exerts significant influence over the cell cycle, the ordered sequence of events that leads to cell division and duplication. Its interference can lead to cell cycle arrest at various checkpoints, thereby inhibiting proliferation. nih.govoncotarget.com
In several cancer cell lines, this compound has been shown to induce cell cycle arrest. For example:
In colorectal cancer (CRC) cells, this compound was found to effectively suppress proliferation by inducing G2/M phase cell cycle arrest. nih.gov This arrest was associated with the reduced activity of the cdc2/cyclin B1 complex, a key regulator of the G2/M transition. nih.gov Specifically, it suppressed the expression of cyclin B1, cdc2, and cdc25c. nih.gov
In rat C6 glioma cells, this compound treatment resulted in cell cycle arrest and an increase in the level of p21Waf1/Cip1, which is an inhibitor of the cyclin E/CDK2 complex. mdpi.com
In the fungus Candida albicans, this compound was observed to affect cell proliferation by arresting cells at the G1/S boundary, delaying the progression of cells from the G1 phase into the S phase. oup.comoup.com
Beyond arresting the cell cycle, this compound can also disrupt mitotic activity. Mitotic arrest has been observed in colorectal cell lines, where this compound inhibits the mitotic kinesin KSP/Eg5. oncotarget.comfrontiersin.org This inhibition leads to the formation of monopolar spindles, a cellular defect that prevents proper chromosome segregation and ultimately halts cell division, leading to an accumulation of cells in the G2/M phase. oncotarget.com In the developing rat brain, this compound significantly reduced mitotic activity in the cerebellar external granular layer. nih.gov
However, in some contexts, such as in developing rat brain subependymal cells, analysis of cell cycle parameters showed no significant changes, although the labelling index was reduced, suggesting an increased turnover time. nih.gov Similarly, in certain chemoresistant glioma cells, the antiproliferative effect was attributed to cell cycle arrest rather than an increase in apoptosis. scienceopen.com
Table 2: Effects of this compound on Cell Cycle and Mitotic Activity
Cell Type | Observed Effect | Mechanism | Reference |
---|---|---|---|
Colorectal Cancer (CRC) Cells | Induces G2/M phase cell cycle arrest. | Decreased activity of cdc2/cyclin B1 complex; suppressed expression of cyclin B1, cdc2, cdc25c. | nih.gov |
Rat C6 Glioma Cells | Cell cycle arrest. | Increased level of p21Waf1/Cip1. | mdpi.com |
Candida albicans | Arrests cells at the G1/S boundary. | Delayed progression from G1 to S phase. | oup.comoup.com |
Colorectal Cell Lines | Induces mitotic arrest. | Inhibition of mitotic kinesin KSP/Eg5, leading to monopolar spindles. | oncotarget.comfrontiersin.org |
Developing Rat Cerebellum | Significantly reduced mitotic activity. | Not specified. | nih.gov |
Neurobiological and Systemic Research Implications of Chlorpromazine
Investigations into Long-Term Neural Adaptations to Chronic Chlorpromazine Exposure
Chronic administration of this compound has been investigated for its effects on the neural landscape over extended periods. Studies have indicated that long-term exposure can modulate adult neurogenesis, the process by which new neurons are generated in the adult brain. Research in rats has shown that chronic this compound treatment can depress the early phase of adult neurogenesis in the subventricular zone (SVZ), evidenced by a decrease in the number of Sox-2 immuno-expressing cells, which are neural progenitor cells. However, a potential neuroprotective effect on developing neuroblasts has also been suggested, implying a complex influence on neural stem/progenitor cell formation and maturation nih.gov. Furthermore, the antipsychotic effects of this compound are thought to arise from long-term adaptations within the brain in response to dopamine receptor blockade drugbank.com. Chronic administration has also been associated with alterations in monoamine levels across various brain regions, with dopamine levels consistently increasing in multiple areas, including the cortex, striatum-accumbens, hippocampus, hypothalamus, cerebellum, and brainstem nih.gov. These adaptations highlight the complex, time-dependent changes the brain undergoes in response to sustained this compound exposure.
Impact on Trace Metal Homeostasis in Specific Central Nervous System Regions
This compound has been observed to influence the delicate balance of trace metals within the central nervous system (CNS), which are critical for numerous neuronal functions.
Alterations in Manganese Concentration
Chronic administration of this compound has been shown to significantly increase manganese concentrations in specific brain regions of guinea pigs. Notably, manganese levels rose significantly in the caudate nucleus and the cerebellar hemisphere following prolonged this compound exposure capes.gov.br.
Changes in Iron Content
Research indicates that chronic this compound treatment can lead to an increase in iron concentration within the brain. Specifically, iron concentration rose most significantly in the caudate nucleus of guinea pigs after long-term administration of the drug capes.gov.br. Further experimental evidence suggests that this compound can stimulate iron uptake by synaptosomes in the rat brain, enhancing the uptake of iron from both iron-citrate and iron-transferrin donors, particularly in cortical synaptosomes nih.gov. Perturbations in iron homeostasis have been linked to neuroleptic-induced extrapyramidal motor side-effects, suggesting a potential role for this compound's influence on iron in these phenomena nih.govembopress.org.
Decreases in Copper Content
Studies have reported a decrease in copper content across all examined brain regions in guinea pigs following chronic this compound administration capes.gov.br. Copper is essential for various brain functions, including iron homeostasis, myelination, and neurotransmitter synthesis, making its reduction a significant observation nih.gov.
Table 1: Impact of Chronic this compound Administration on Trace Metal Concentrations in Guinea Pig Brain Regions
Brain Region | Trace Metal | Observed Change (Chronic this compound) | Reference |
---|---|---|---|
Caudate Nucleus | Manganese | Significant Increase | capes.gov.br |
Caudate Nucleus | Iron | Most Significant Increase | capes.gov.br |
Caudate Nucleus | Copper | Decrease | capes.gov.br |
Frontal Cortex | Manganese | Alteration (not specified as significant increase/decrease) | capes.gov.br |
Frontal Cortex | Iron | Alteration (not specified as significant increase/decrease) | capes.gov.br |
Frontal Cortex | Copper | Decrease | capes.gov.br |
Cerebellar Hemisphere | Manganese | Significant Increase | capes.gov.br |
Cerebellar Hemisphere | Iron | Alteration (not specified as significant increase/decrease) | capes.gov.br |
Cerebellar Hemisphere | Copper | Decrease | capes.gov.br |
Studies on this compound's Influence on Neuroplasticity and Synaptic Remodeling
This compound's impact extends to neuroplasticity, the brain's ability to adapt and reorganize its structure and function. Research indicates that this compound can influence markers of neural plasticity. For instance, studies have shown that this compound up-regulates the expression of polysialic acid (PolySia) in human neuroblastoma cells and, importantly, in the prefrontal cortex of adult mice mdpi.com. PolySia-NCAM is a key molecule involved in neural plasticity, synaptic remodeling, and neuronal migration, and its altered expression has been implicated in psychiatric disorders like schizophrenia mdpi.comnih.govresearchgate.net. Beyond this specific marker, antipsychotic drugs, in general, are understood to induce neuroplasticity, leading to anatomical and molecular changes in the brain, which are considered important for their therapeutic effects nih.gov. These changes can include alterations in synapse morphology and number, as well as modifications in protein phosphorylation and gene expression, collectively contributing to the remodeling of neural circuits nih.govnih.gov.
Contributions to the Development and Validation of Animal Models for Psychiatric Disorders
This compound has played a pivotal role in the historical development and ongoing validation of animal models for psychiatric disorders, particularly schizophrenia. Early in psychopharmacology, this compound, as the first effective antipsychotic, served as a benchmark drug for screening and characterizing new compounds and for establishing early animal models nih.govnih.govscielo.br. Many animal models used to study schizophrenia and antipsychotic drugs were initially developed based on the behavioral effects observed with this compound and similar early antipsychotics nih.govscielo.br. These models often involve inducing specific behavioral or neurochemical changes in animals that mimic aspects of human psychiatric conditions, such as amphetamine-induced hyperactivity or deficits in prepulse inhibition of the startle reflex, which are then used to test the efficacy of potential treatments nih.govnih.govscielo.br. The ability of a drug to reverse these induced states or to modulate specific behavioral readouts became a standard for validating these models and predicting antipsychotic efficacy nih.govscielo.brresearchgate.net. Thus, this compound's historical significance lies not only in its therapeutic impact but also in its foundational contribution to the methodologies used to understand and treat complex brain disorders through preclinical research.
Q & A
Q. How are chlorpromazine dose equivalencies calculated for comparative antipsychotic studies?
To establish dose equivalence, researchers use fixed-dose placebo-controlled studies to identify minimum effective doses (MED) of newer antipsychotics relative to haloperidol. Using the convention "2 mg haloperidol = 100 mg this compound," MED ratios are converted. For example:
Q. What methodological strategies mitigate confounding variables (e.g., prolactin levels) in this compound studies?
- Covariate Adjustment: Use analysis of covariance (ANCOVA) with this compound-equivalent doses and sex as covariates to isolate drug-specific effects on prolactin .
- Post Hoc Testing: Apply Bonferroni corrections to reduce Type I errors in multi-group comparisons .
- Longitudinal Sampling: Track prolactin levels at consistent time points to account for circadian fluctuations.
Advanced Research Question
Q. How can contradictory findings between in vitro and in vivo this compound studies be resolved?
- Replication Controls: For in vitro assays (e.g., UV-spectrophotometric DNA damage studies), include irradiated controls and standardized this compound concentrations (4–20 µg/mL) to validate dose-response consistency .
- Pharmacokinetic Modeling: Adjust for metabolic differences (e.g., 7-hydroxy this compound activity) using high-performance liquid chromatography (HPLC) to quantify plasma metabolites .
- Species-Specific Calibration: In animal models, calibrate doses based on behavioral endpoints (e.g., treadle pressing in pigeons) rather than human equivalencies .
Basic Research Question
Q. What are key considerations for designing longitudinal studies on this compound's long-term effects?
- Multi-Method Assessment: Combine psychiatric evaluations, psychometric tests, and social case studies to capture diverse endpoints .
- Blinding Protocols: Use placebo-controlled, double-blind designs to minimize bias in long-term trials .
- Retention Strategies: Implement regular follow-ups and incentivize participation to reduce attrition.
Advanced Research Question
Q. How should researchers address discrepancies in this compound's dose-response relationships?
- Meta-Regression Analysis: Test variables like age, trial quality (Jadad scale), and dose (this compound equivalents) to identify moderators of effect size .
- Sensitivity Analyses: Exclude outlier studies or apply random-effects models to account for heterogeneity .
- Dose-Titration Studies: Use adaptive designs to dynamically adjust doses based on individual pharmacokinetic profiles .
Basic Research Question
Q. What safety protocols are critical for handling this compound in laboratory settings?
- Personal Protective Equipment (PPE): Wear nitrile gloves, lab coats, and eye protection to prevent skin/eye contact (H315, H319) .
- Ventilation: Store and handle solutions in fume hoods to avoid inhalation of acetonitrile solvent vapors .
- Waste Disposal: Classify this compound waste as "strongly hazardous to water" (WGK 3) and follow REACH regulations for disposal .
Advanced Research Question
Q. What experimental controls are essential when studying this compound's impact on endocytosis?
- Inhibitor Specificity: Use this compound (clathrin inhibitor) alongside caveolin-1/dynamin inhibitors to isolate pathways .
- Negative Controls: Include mock-treated samples (e.g., medium-only) to baseline UV spectrophotometry readings .
- Dose Validation: Confirm non-cytotoxic concentrations via cell viability assays prior to endocytosis experiments.
Basic Research Question
Q. How are active metabolites like 7-hydroxy this compound quantified in pharmacokinetic studies?
- Chromatography: Use HPLC with UV detection (λ = 260 nm) and reference standards (e.g., 25 µL sample at 10 mM) .
- Plasma Sampling: Collect timed post-dose samples to track metabolite accumulation .
- Cross-Species Validation: Compare rodent and human metabolite profiles to assess translational relevance.
Advanced Research Question
Q. What statistical approaches validate this compound's behavioral effects in animal models?
- Multiple-Schedule Testing: Assess appetitive/aversive responses using operant conditioning (e.g., treadle pressing) to differentiate sedation from motor impairment .
- Dose-Response Curves: Fit data to sigmoidal models (e.g., Hill equation) to estimate EC50 values .
- Species-Specific Adjustments: Calibrate doses for interspecies metabolic differences (e.g., avian vs. mammalian models) .
Advanced Research Question
Q. How do researchers reconcile conflicting this compound plasma level data with clinical outcomes?
- Single-Dose Pharmacokinetics: Measure response to a test dose rather than sustained levels to predict individual efficacy .
- Parent Compound Focus: Prioritize this compound (vs. metabolites) in initial assays to simplify dose-response correlations .
- Population Stratification: Subgroup patients by CYP2D6 metabolizer status to explain variability in plasma levels .
Retrosynthesis Analysis
AI-Powered Synthesis Planning: Our tool employs the Template_relevance Pistachio, Template_relevance Bkms_metabolic, Template_relevance Pistachio_ringbreaker, Template_relevance Reaxys, Template_relevance Reaxys_biocatalysis model, leveraging a vast database of chemical reactions to predict feasible synthetic routes.
One-Step Synthesis Focus: Specifically designed for one-step synthesis, it provides concise and direct routes for your target compounds, streamlining the synthesis process.
Accurate Predictions: Utilizing the extensive PISTACHIO, BKMS_METABOLIC, PISTACHIO_RINGBREAKER, REAXYS, REAXYS_BIOCATALYSIS database, our tool offers high-accuracy predictions, reflecting the latest in chemical research and data.
Strategy Settings
Precursor scoring | Relevance Heuristic |
---|---|
Min. plausibility | 0.01 |
Model | Template_relevance |
Template Set | Pistachio/Bkms_metabolic/Pistachio_ringbreaker/Reaxys/Reaxys_biocatalysis |
Top-N result to add to graph | 6 |
Feasible Synthetic Routes
Featured Recommendations
Most viewed | ||
---|---|---|
Most popular with customers |
Disclaimer and Information on In-Vitro Research Products
Please be aware that all articles and product information presented on BenchChem are intended solely for informational purposes. The products available for purchase on BenchChem are specifically designed for in-vitro studies, which are conducted outside of living organisms. In-vitro studies, derived from the Latin term "in glass," involve experiments performed in controlled laboratory settings using cells or tissues. It is important to note that these products are not categorized as medicines or drugs, and they have not received approval from the FDA for the prevention, treatment, or cure of any medical condition, ailment, or disease. We must emphasize that any form of bodily introduction of these products into humans or animals is strictly prohibited by law. It is essential to adhere to these guidelines to ensure compliance with legal and ethical standards in research and experimentation.